Skip to main content

Table 1 Clinical characteristics of patients prescribed metoclopramide

From: A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)

Characteristic

Continuers

(n = 6)

Discontinuers

(n = 8)

Total

(n = 14)

Mean age at data collection (years ± SD)

47.8 (± 8.1)

40.8 (± 12.1)

43.8 (± 10.8)

Female gender (%)

2(16.7)

4 (50)

6 (35.7)

Mean clozapine dose (mg ± SD)

362.5 (± 106.9)

325 (± 73.2)

341.1 (± 87.5)

Mean duration of treatment of metoclopramide (years ± SD)

1.9 (± 1.5)

0.7 (± 0.9)

1.2 (± 1.3)

Mean metoclopramide dose (mg ± SD)

21.7 (± 7.5)

18.8 (± 9.9)

20 (± 8.8)

Median metoclopramide dose (IQR)

20 (10)

15 (20)

20 (20)

Metoclopramide monotherapy %

5 (83.3)

3 (37.5)

8 (57.1)

Adverse reactions reported (%)

2 (33.3)

3 (37.5)

5 (35.7)

  1. IQR Interquartile range, SD Standard deviation